-
EP3411411
European procedure
Extract from the Register of European Patents
EP About this file: EP3411411
| EP3411411 - 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS [Right-click to bookmark this link] | |||
| Former [2018/50] | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | ||
| [2021/01] | Status | The patent has been limited Status updated on 24.12.2021 Database last updated on 20.07.2024 | |
| Former | The patent has been granted Status updated on 16.04.2021 | ||
| Former | Grant of patent is intended Status updated on 13.12.2020 | ||
| Former | Examination is in progress Status updated on 04.07.2020 | ||
| Former | Request for examination was made Status updated on 09.11.2018 | ||
| Former | The international publication has been made Status updated on 11.08.2017 | Most recent event Tooltip | 25.03.2022 | No opposition filed within time limit | published on 27.04.2022 [2022/17] | Applicant(s) | For all designated states Biocryst Pharmaceuticals, Inc. 4505 Emperor Blvd. Durham, North Carolina 27703 / US | [2018/50] | Inventor(s) | 01 /
KOTIAN, Pravin, L. 1139 Magnolia Run Hoover, Alabama 35226 / US | 02 /
BABU, Yarlagadda, S. 4836 Southlake Parkway Birmingham AL 35244 / US | 03 /
ZHANG, Weihe 2645 Manchester Court Vestavia AL 35226 / US | 04 /
VOGETI, Lakshminarayana 905 Congressional Drive Lawrence, Kansas 66049 / US | 05 /
WU, Minwan 2709 Paden Trail Vestavia Hills AL 35226 / US | 06 /
CHINTAREDDY, Venkat, R. 3134 Renfro Road Vestavia Hills, Alabama 35216 / US | 07 /
RAMAN, Krishnan 3739 Spearman Drive Birmingham AL 35244 / US | [2018/50] | Representative(s) | HGF HGF Limited 1 City Walk Leeds LS11 9DX / GB | [2022/04] |
| Former [2021/20] | HGF 1 City Walk Leeds LS11 9DX / GB | ||
| Former [2018/50] | HGF Limited 1 City Walk Leeds LS11 9DX / GB | Application number, filing date | 17748044.9 | 01.02.2017 | [2018/50] | WO2017US15953 | Priority number, date | US201662289653P | 01.02.2016 Original published format: US 201662289653 P | [2018/50] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2017136395 | Date: | 10.08.2017 | Language: | EN | [2017/32] | Type: | A1 Application with search report | No.: | EP3411411 | Date: | 12.12.2018 | Language: | EN | The application published by WIPO in one of the EPO official languages on 10.08.2017 takes the place of the publication of the European patent application. | [2018/50] | Type: | B1 Patent specification | No.: | EP3411411 | Date: | 19.05.2021 | Language: | EN | [2021/20] | Type: | B3 Limited patent | No.: | EP3411411 | Date: | 26.01.2022 | Language: | EN | [2022/04] | Search report(s) | International search report - published on: | US | 10.08.2017 | (Supplementary) European search report - dispatched on: | EP | 30.07.2019 | Classification | IPC: | C07D401/12, C07D231/56, C07D209/40, C07D209/42, C07D209/48, C07D487/04, C07D471/04, C07D403/12, C07D403/04, C07D403/06, A61K31/416, A61K31/4439, A61K31/404, A61K31/4035, A61P37/00, A61P37/06, A61P25/00, A61P25/28, A61P13/12, A61P9/00, A61P21/04, // C07D401/04, C07D401/06, C07D401/14, C07D405/12, C07D209/12, A61P13/00 | [2021/01] | CPC: |
A61K31/416 (EP,IL,US);
C07D209/12 (EP,IL,KR,US);
C07K5/06139 (CN);
A61K31/403 (IL,KR);
A61K31/4439 (IL,KR);
A61K31/519 (IL,KR);
A61P11/00 (CN);
A61P11/06 (CN);
A61P13/00 (EP,IL,US);
A61P13/10 (IL,US);
A61P13/12 (CN);
A61P15/00 (CN);
A61P17/00 (CN);
A61P19/02 (CN);
A61P21/04 (EP,CN,IL,US);
A61P25/00 (CN);
A61P25/28 (EP,CN,IL,US);
A61P29/00 (CN);
A61P37/06 (EP,CN,IL,US);
A61P7/00 (CN);
A61P9/00 (EP,CN,IL,US);
A61P9/10 (CN);
C07D209/30 (IL,US);
C07D209/40 (EP,CN,IL,US);
C07D209/42 (EP,IL,US);
C07D209/48 (EP,IL,US);
C07D231/56 (EP,IL,KR,US);
C07D401/04 (EP,IL,KR,US);
C07D401/06 (EP,IL,US);
C07D401/12 (EP,IL,KR,US);
C07D401/14 (EP,IL,US);
C07D403/04 (EP,IL,US);
C07D403/06 (EP,IL,KR,US);
C07D403/12 (EP,IL,KR,US);
C07D405/12 (EP,IL,KR,US);
C07D471/04 (EP,IL,US);
|
| Former IPC [2019/35] | C07D401/12, C07D231/56, C07D209/40, C07D209/48, C07D487/04, C07D471/04, A61K31/416, A61K31/4439, A61K31/404, A61K31/4035, A61P37/00, A61P37/06, A61P25/00, A61P25/28, A61P13/12, A61P9/00, A61P21/04 | ||
| Former IPC [2018/50] | C07K16/28, A61K39/00, A61P9/00, A61P37/06 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/50] | Extension states | BA | 20.08.2018 | ME | 20.08.2018 | Validation states | MA | 20.08.2018 | MD | 20.08.2018 | Title | German: | 1H-INDAZOL-3-CARBOXAMID-DERIVATE UND ÄHNLICHE VERBINDUNGE ALS FAKTOR D INHIBITOREN ZUR BEHANDLUNG VON DURCH EINE ABERRANTE AKTIVITÄT DES KOMPLEMENTSYSTEMS GEKENNZEICHNET ERKRANKUNGEN, WIE Z.B. IMMUNOLOGISCHE STÖRUNGEN | [2021/47] | English: | 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS | [2021/01] | French: | DÉRIVÉS DE 1H-INDAZOLE-3-CARBOXAMIDE ET COMPOSÉS SIMILAIRES EN TANT QU'INHIBITEURS DU FACTEUR D POUR LE TRAITEMENT DE MALADIES CHARACTERISÉS PAR UNE ACTIVITÉ ABERRANTE DU SYSTÈME COMPLÉMENTAIRE, COMME P.E. TROUBLES IMMUNOLOGIQUES | [2021/01] |
| Former [2018/50] | BENZOPYRAZOLVERBINDUNGEN UND ANALOGA DAVON | ||
| Former [2018/50] | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | ||
| Former [2018/50] | COMPOSÉS BENZOPYRAZOLE ET ANALOGUES DE CEUX-CI | Entry into regional phase | 20.08.2018 | National basic fee paid | 20.08.2018 | Search fee paid | 20.08.2018 | Designation fee(s) paid | 20.08.2018 | Examination fee paid | Examination procedure | deleted | Date on which the examining division has become responsible | 20.08.2018 | Examination requested [2018/50] | 02.03.2020 | Amendment by applicant (claims and/or description) | 08.07.2020 | Despatch of a communication from the examining division (Time limit: M04) | 25.09.2020 | Reply to a communication from the examining division | 14.12.2020 | Communication of intention to grant the patent | 09.04.2021 | Fee for grant paid | 09.04.2021 | Fee for publishing/printing paid | 09.04.2021 | Receipt of the translation of the claim(s) | Divisional application(s) | EP21173901.6 / EP3925956 | Opposition(s) | 22.02.2022 | No opposition filed within time limit [2022/17] | Limitations: | 09.06.2021 | Date of receipt of request for limitation | admissible | 26.10.2021 | Communication of intention to limit the patent | 17.12.2021 | Fee for printing patent specification after limitation | Fees paid | Renewal fee | 13.02.2019 | Renewal fee patent year 03 | 13.02.2020 | Renewal fee patent year 04 | 12.02.2021 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [X]WO2004087743 (COUNCIL SCIENT IND RES [IN]) [X] 1-15 * page 18; example 6 * * N-[2-(1H-benzimidazol-1-yl)acetyl]-3-cyclohexyl-L-alanyl-L-Tryptophan; RN: 1348864-05-0 *; | [A]WO2009106980 (PFIZER [US], et al) [A] 1-18 * page 61, paragraph 3 - paragraph 4 * * example - ** claims 1, 12 *; | [X]WO2010045580 (EXELIXIS INC [US], et al) [X] 1-15 * page 56; table 1; compound 212 * * page 63; table 1; compound 322 * * page 65 - page 66; table 1; compounds 352, 364 * * claims 8, 10, 13, 17 *; | [X]WO2012065062 (PHARMARESOURCES SHANGHAI CO LTD [CN], et al) [X] 1-15 * page 94; example 125 * * page 119 - page 127; examples 171-174G * * page 136 - page 145; examples 183-212 * * page 154 - page 157; compounds 232, 234, 235, 240-243, 246, 251-253 * * claims 1-5, 9-18, 21, 45, 50 *; | [A]WO2012093101 (NOVARTIS AG [CH], et al) [A] 1-18 * example - * * claims 1, 18, 20-23 *; | [A]WO2015130854 (ACHILLION PHARMACEUTICALS INC [US]) [A] 1-18 * example - * * claims 1, 2, 5, 7, 11 *; | [X] - ABDEL-RAHMAN, ADEL A.-H. ET AL, "Amino Acid Derivatives, VII [1]: Synthesis and Antiviral Evaluation of .alpha.-Amino Acid Esters Bearing an Indazole Side Chain", MONATSHEFTE FUER CHEMIE, (20080212), vol. 139, no. 3, doi:10.1007/s00706-007-0770-7, ISSN 0026-9247, pages 289 - 297, XP002792919 [X] 1-15 * page 291; compounds 22-28 * DOI: http://dx.doi.org/10.1007/s00706-007-0770-7 | [X] - MARTIN, ADAM D ET AL, "Effect of heterocyclic capping groups on the self-assembly of a dipeptide hydrogel", SOFT MATTER, (20160122), vol. 12, no. 10, doi:10.1039/C6SM00025H, pages 2700 - 2707, XP002792920 [X] 1-14 * page 2701; compounds 1, 2, 4 * DOI: http://dx.doi.org/10.1039/C6SM00025H | [X] - HAYS, ANNA-MARIA A., "Trapping of peptide-based surrogates in an artificially created channel of cytochrome c peroxidase", PROTEIN SCIENCE, (200302), vol. 12, no. 2, doi:10.1110/ps.0228403, ISSN 0961-8368, pages 278 - 287, XP002792921 [X] 1-14 * page 281; figure 3; compounds 15, 16 * DOI: http://dx.doi.org/10.1110/ps.0228403 | International search | [A]US2014275080 (FLYNN DANIEL L [US], et al) [A] 1, 3 * entire document *; | [A]US2015105367 (FLYNN DANIEL L [US], et al) [A] 1, 3 * entire document *; | [PX]WO2016205010 (UNIV CALIFORNIA [US]) [PX] 1, 3* entire document *; | [A] - PUBCHEM, (20110328), Database accession no. 115755424, XP055403857 [A] 1, 3 * . entire document * | by applicant | US4559157 | US4608392 | US4733655 | US4800882 | US4820508 | US4886062 | US4938949 | WO9013332 | US4992478 | WO9112779 | US5102417 | US5419760 | US5429634 | US6770729 | WO2004087743 | US2004243225 | WO2009106980 | WO2010045580 | US2011230462 | WO2012065062 | WO2012093101 | WO2013014102 | WO2013040215 | WO2014002053 | WO2014049047 | WO2015130854 | - MARRIDES, S., Pharmacological Reviews, (19980000), vol. 50, pages 59 - 88 | - MORGAN, B., Eur J Clin Invest, (19940000), vol. 24, pages 219 - 228 | - ADEL et al., Monatsch Chem, (20080000), vol. 139, pages 289 - 297 | - MARTIN et al., SoftMatter, (20190000), vol. 12, pages 2700 - 2707 | - HAYS et al., Protein Science, (20030000), vol. 12, pages 278 - 287 |